In a major endorsement of Sangamo Therapeutics’ zinc finger nuclease (ZFN) genome editing technology, Gilead Sciences’ Kite Pharma has secured an exclusive licence to use the platform for the development of next-generation ex vivo cellular immunotherapies in oncology for both autologous and allogeneic use. The deal strengthens Gilead’s position as a leading player in the cellular therapy space following its acquisitions of Kite and Cell Design Labs.